Table 3.

Stepwise Cox regression analysis of patency for externally supported AVG and other confounding factors (n = 4402)

Variable	Crude			Adjusted
	HR	95% CI	P	HR	95% CI	P
Graft type (base = externally supported AVG)	1.45	1.34 to 1.58	<0.0001	1.46	1.34 to 1.59	<0.0001
Gender (base = female)	1.11	1.03 to 1.19	0.0045	1.12	1.04 to 1.20	0.0021
Age (base = 18 to 44 years)
45 to 64	0.93	0.80 to 1.08	0.3634	0.96	0.82 to 1.12	0.5875
65 to 74	1.07	0.92 to 1.25	0.3522	1.12	0.97 to 1.31	0.1307
≥75	1.18	1.01 to 1.37	0.0421	1.21	1.04 to 1.41	0.0168
Time of vascular access creation (base = after initiating dialysis)
before initiating dialysis	0.76	0.71 to 0.82	<0.0001	0.776	0.71 to 0.82	<0.0001
Comorbidities
myocardial infarct (base = no)	1.03	0.84 to 1.26	0.8016
congestive heart failure (base = no)	1.13	1.06 to 1.22	0.0006	1.15	1.07 to 1.24	0.0001
peripheral vascular disease (base = no)	1.03	0.90 to 1.18	0.7033
cerebrovascular disease (base = no)	1.00	0.92 to 1.10	0.9547
dementia (base = no)	1.00	0.80 to 1.27	0.9698
chronic pulmonary disease (base = no)	1.10	1.01 to 1.21	0.0330
rheumatologic disease (base = no)	0.93	0.74 to 1.15	0.4894
ulcer disease (base = no)	1.05	0.97 to 1.14	0.2205
mild liver disease (base = no)	1.04	0.90 to 1.21	0.5754
mild diabetes mellitus (base = no)	1.01	0.95 to 1.08	0.3608
severe diabetes mellitus (base = no)	1.03	0.97 to 1.10	0.7417
hemiplegia or paraplegia (base = no)	1.04	0.83 to 1.31	0.7353
malignancy (base = no)	1.05	0.94 to 1.18	0.3931
moderate or severe liver disease (base = no)	0.81	0.57 to 1.15	0.2319
metastatic solid tumor (base = no)	1.17	0.80 to 1.71	0.4076
Antiplatelet and anticoagulant medication (%)
aspirin	0.99	0.99 to 0.99	<0.0001	0.99	0.99 to 1.00	<0.0001
clopidogrel	0.99	0.99 to 1.00	0.0542	1.00	0.99 to 1.00	0.0220
warfarin	1.00	0.99 to 1.02	0.6367